Elevated urokinase-type plasminogen activator receptor expression in a colon cancer cell line is due to a constitutively activated extracellular signal-regulated kinase-1-dependent signaling cascade (original) (raw)
- Original Paper
- Published: 29 May 1997
Oncogene volume 14, pages 2563–2573 (1997)Cite this article
- 344 Accesses
- 60 Citations
- Metrics details
Abstract
The urokinase-type plasminogen activator receptor (u-PAR) facilitates extracellular matrix degradation in part by accelerating plasmin formation at the cell surface. We previously reported that u-PAR expression is elevated in colon cancer cell lines characterized by their in vitro invasive capacity. Since, u-PAR expression is increased by a variety of growth factors, which signal through the extracellular signal-regulated kinases 1 and 2 (ERK1/ERK2), we determined if these mitogen-activated protein kinases (MAPKs) regulate u-PAR expression in two cultured colon cancer cell lines. An in-gel kinase assay showed that ERK1 activity was considerably higher in RKO cells, which display ⩾105 receptors/cell, than the GEO cells which have ≃104 urokinase receptors per cell. The expression of either an ERK-inactivating phosphatase (CL100), or a kinase-defective ERK1, decreased the activity of a u-PAR promoter-driven CAT reporter in RKO cells. Immune complex kinase assays indicated that the constitutive ERK1 activity in RKO cells was largely a result of an activated MEK1. Further, treatment of RKO cells with a specific inhibitor (PD 098059) of MEK1 activation, which diminished ERK1 activity, reduced the amount of urokinase specifically bound to the cell surface and this was associated with reduced laminin degradation. The expression of a dominant negative c-Raf-1 also reduced u-PAR promoter activity suggesting that MEK1 activation involved an activator at, or upstream, of this serine-threonine kinase. Transfection of the u-PAR-deficient GEO cells with a constitutively activated MEK1 expression construct up-regulated u-PAR promoter activity. Similarly treatment of GEO cells with a phosphatase inhibitor (sodium vanadate) caused a dose-dependent increase in ERK1 activity which paralleled increased cell surface binding of urokinase. Taken together, these data suggest that elevated u-PAR expression, in at least a sub-population of colon cancer, is partly a consequence of a constitutively activated ERK-1-dependent signaling cascade.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
Similar content being viewed by others
Author information
Authors and Affiliations
- Departments of Tumor Biology/Head and Neck Surgery, MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, Texas, USA
H Wang, R Gum, C Simon & D Boyd - Mucosal Inflammation and Cancer Group, Divison of Molecular Medicine, John Curtin School of Medical Research, ANU, ACT 2601, Australia
Y Wang - Department of Obstetrics and Gynecology, Technical University of Munich, Germany
E Lengyel
Authors
- E Lengyel
You can also search for this author inPubMed Google Scholar - H Wang
You can also search for this author inPubMed Google Scholar - R Gum
You can also search for this author inPubMed Google Scholar - C Simon
You can also search for this author inPubMed Google Scholar - Y Wang
You can also search for this author inPubMed Google Scholar - D Boyd
You can also search for this author inPubMed Google Scholar
Rights and permissions
About this article
Cite this article
Lengyel, E., Wang, H., Gum, R. et al. Elevated urokinase-type plasminogen activator receptor expression in a colon cancer cell line is due to a constitutively activated extracellular signal-regulated kinase-1-dependent signaling cascade.Oncogene 14, 2563–2573 (1997). https://doi.org/10.1038/sj.onc.1201098
- Received: 04 November 1996
- Revised: 13 February 1997
- Accepted: 13 February 1997
- Issue Date: 29 May 1997
- DOI: https://doi.org/10.1038/sj.onc.1201098